Northwest Bioth Cmn (NWBO): Price and Financial Metrics


Northwest Bioth Cmn (NWBO): $0.69

0.01 (+1.60%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NWBO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NWBO POWR Grades


  • Growth is the dimension where NWBO ranks best; there it ranks ahead of 56.78% of US stocks.
  • NWBO's strongest trending metric is Value; it's been moving up over the last 179 days.
  • NWBO's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

NWBO Stock Summary

  • With a price/earnings ratio of 3.74, Northwest Biotherapeutics Inc P/E ratio is greater than that of about only 3.26% of stocks in our set with positive earnings.
  • With a price/sales ratio of 665.81, Northwest Biotherapeutics Inc has a higher such ratio than 99.31% of stocks in our set.
  • NWBO's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 5.36% of US stocks.
  • Stocks that are quantitatively similar to NWBO, based on their financial statements, market capitalization, and price volatility, are QLYS, BOX, LYFT, PACB, and MPWR.
  • NWBO's SEC filings can be seen here. And to visit Northwest Biotherapeutics Inc's official web site, go to www.nwbio.com.

NWBO Valuation Summary

  • NWBO's price/earnings ratio is -2.4; this is 106.58% lower than that of the median Healthcare stock.
  • Over the past 239 months, NWBO's price/sales ratio has gone up 173.7.
  • NWBO's price/sales ratio has moved up 173.7 over the prior 239 months.

Below are key valuation metrics over time for NWBO.

Stock Date P/S P/B P/E EV/EBIT
NWBO 2021-08-31 831.8 -3.3 -2.4 -2.5
NWBO 2021-08-30 793.7 -3.1 -2.3 -2.4
NWBO 2021-08-27 825.5 -3.2 -2.4 -2.5
NWBO 2021-08-26 876.3 -3.4 -2.5 -2.6
NWBO 2021-08-25 857.2 -3.4 -2.5 -2.6
NWBO 2021-08-24 761.9 -3.0 -2.2 -2.3

NWBO Growth Metrics

    The year over year price growth rate now stands at 413.16%.
  • Its 3 year net income to common stockholders growth rate is now at 42.34%.
  • The 4 year cash and equivalents growth rate now stands at -93.86%.
Over the past 52 months, NWBO's revenue has gone up $630,000.

The table below shows NWBO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 1.005 -38.299 179.126
2021-09-30 1.508 -37.256 -234.493
2021-06-30 1.374 -38.265 -474.108
2021-03-31 0.96 -37.802 -536.47
2020-12-31 1.291 -32.093 -529.821
2020-09-30 1.685 -27.868 -242.649

NWBO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NWBO has a Quality Grade of C, ranking ahead of 27.35% of graded US stocks.
  • NWBO's asset turnover comes in at 0.045 -- ranking 328th of 682 Pharmaceutical Products stocks.
  • EDSA, BLCM, and GLYC are the stocks whose asset turnover ratios are most correlated with NWBO.

The table below shows NWBO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.045 1 1.610
2021-03-31 0.036 1 2.337
2020-12-31 0.061 1 3.470
2020-09-30 0.112 1 3.430
2020-06-30 0.190 1 1.815
2020-03-31 0.245 1 -0.306

NWBO Stock Price Chart Interactive Chart >

Price chart for NWBO

NWBO Price/Volume Stats

Current price $0.69 52-week high $2.05
Prev. close $0.68 52-week low $0.39
Day low $0.68 Volume 1,949,024
Day high $0.73 Avg. volume 3,226,374
50-day MA $0.90 Dividend yield N/A
200-day MA $0.97 Market Cap 700.86M

Northwest Bioth Cmn (NWBO) Company Bio


Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies. The company was founded in 1996 and is based in Bethesda, Maryland.


NWBO Latest News Stream


Event/Time News Detail
Loading, please wait...

NWBO Latest Social Stream


Loading social stream, please wait...

View Full NWBO Social Stream

Latest NWBO News From Around the Web

Below are the latest news stories about Northwest Biotherapeutics Inc that investors may wish to consider to help them evaluate NWBO as an investment opportunity.

Northwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK Facility

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced commencement of production of its first dendritic cell cancer vaccine for a compassionate use patient at its recently licensed production facility in Sawston, UK.

Yahoo | February 17, 2022

Northwest Biotherapeutics Announces MHRA Approval Of License for GMP Manufacturing At Sawston, UK Facility

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that approval has been received from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) of a license for manufacture of GMP (clinical grade) cell therapy products at its Sawston, UK facility.

Yahoo | December 21, 2021

Northwest Biotherapeutics Announces $15 Million Financing

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of a $15 million financing on November 22, 2021, which brought the Company's cash reserves above $20 million.

Yahoo | November 29, 2021

Northwest Biotherapeutics Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the completion of two key milestones which are required for production of DCVax products at the Company's manufacturing facility in Sawston, UK, and which have been a major focus since the completion of initial construction last year.

Yahoo | October 28, 2021

UK Manufacturing Facility & Phase III Trial Updates From Northwest Biotherapeutics (OTCQB: NWBO)

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that an application for certification of the manufacturing facility in Sawston, UK has been submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA). The Company also provided a process update on the DCVax®-L Phase III Trial.

Yahoo | May 12, 2021

Read More 'NWBO' Stories Here

NWBO Price Returns

1-mo -26.45%
3-mo -25.79%
6-mo -14.81%
1-year -58.93%
3-year 116.78%
5-year 294.29%
YTD -1.43%
2021 -54.10%
2020 609.63%
2019 4.57%
2018 -12.63%
2017 -32.43%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0638 seconds.